Watson receives regulatory approval for generic Prograf
MORRISTOWN, N.J. The Food and Drug Administration has approved a drug made by Watson Pharmaceuticals for treating organ transplant patients, Watson said Friday.
Watson announced the approval of tacrolimus capsules in the 5 mg strength.
The drug is a version of Astellas’ Prograf, used to prevent rejection rejection of transplanted livers, kidneys and hearts. Program had sales of around $108 million during the 12-month period ended in May, according to IMS Health.